Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - The Lancet …, 2022 - thelancet.com
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …
被引用次数：33 相关文章

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz… - The lancet …, 2022 - mdanderson.elsevierpure.com
Background: Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz… - The lancet …, 2022 - repository.uantwerpen.be
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz… - The Lancet …, 2022 - research-repository.uwa.edu.au
Background: Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …
[HTML] nih.gov

[HTML][HTML] Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - The Lancet …, 2022 - ncbi.nlm.nih.gov
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - THE LANCET …, 2022 - iris.unito.it
Few treatment options exist for second-line treatment of malignant pleural mesothelioma.
We aimed to assess the antibody-drug conjugate anetumab ravtansine versus vinorelbine in …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

LK Hedy, S Novello, A Bearz, LC Giovanni… - THE LANCET …, 2022 - sfera.unife.it
Background: Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - The Lancet …, 2022 - Elsevier
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 …

HL Kindler, S Novello, A Bearz, GL Ceresoli… - The Lancet …, 2022 - thelancet.com
Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …